Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

53
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.5K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRYAB is compromised in pathologically affected oligodendrocytes in multiple system atrophy.

Brain pathology (Zurich, Switzerland)·2026
Same author

Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.

Brain, behavior, & immunity - health·2026
Same author

Ultra-rare variants in LAMA2 are risk factors for frontotemporal dementia and motor neuron disease.

Human molecular genetics·2026
Same author

Location and mapping of the human rostromedial tegmental nucleus and associated midbrain inhibitory nuclei regulating dopamine neurons.

Brain structure & function·2026
Same author

Systemic dysregulation of apolipoproteins in amyotrophic lateral sclerosis serum.

FEBS open bio·2026
Same author

Alpha-Synuclein in Neurodegeneration: From Shared Biology to Disease-Specific Phenotypes.

Cells·2026

Related Experiment Video

Updated: May 3, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K

Lipid dysfunction and pathogenesis of multiple system atrophy.

Jonathan M Bleasel, Joanna H Wong, Glenda M Halliday

  • 1Neuroscience Research Australia, Barker St, Randwick, Sydney NSW 2031, Australia. w.kim@unsw.edu.au.

Acta Neuropathologica Communications
|February 8, 2014
PubMed
Summary
This summary is machine-generated.

Multiple system atrophy (MSA) involves α-synuclein buildup in oligodendrocytes. This review explores how lipid metabolism and membrane transporters may drive this unique neurodegenerative disease.

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K
Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

5.3K

Related Experiment Videos

Last Updated: May 3, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K
Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

5.3K

Area of Science:

  • Neurobiology
  • Neurodegenerative Diseases
  • Lipid Metabolism

Background:

  • Multiple system atrophy (MSA) is a progressive neurodegenerative disease.
  • Pathology involves α-synuclein accumulation in oligodendrocytes within the central nervous system (CNS).
  • Disordered lipid metabolism is implicated in neurodegeneration, with α-synuclein's role in oligodendrocytes being unclear.

Purpose of the Study:

  • To review evidence on the role of membrane transporters and lipid dyshomeostasis in MSA pathogenesis.
  • To explore the potential mechanisms linking lipid metabolism to α-synuclein aggregation in MSA.
  • To hypothesize how oligodendrocyte lipid metabolism contributes to MSA's unique neuropathology.

Main Methods:

  • Literature review synthesizing current evidence.
  • Analysis of existing research on α-synuclein, lipid metabolism, and membrane transport in neurodegenerative diseases.
  • Exploration of genetic findings, including COQ2 mutations, in MSA.

Main Results:

  • α-synuclein aggregation is a hallmark of MSA, primarily in oligodendrocytes.
  • Lipid homeostasis is crucial in the CNS, and its disruption may promote α-synuclein aggregation.
  • COQ2 gene mutations highlight the role of membrane transporters and coenzyme Q10 biosynthesis in MSA.

Conclusions:

  • Dysregulation of specialized lipid metabolism in oligodendrocytes is hypothesized to underlie MSA neuropathology.
  • Membrane transporters and lipid dyshomeostasis are likely central to MSA pathogenesis.
  • Further research is needed to clarify the precise mechanisms involved in myelin degeneration in MSA.